Avalo Therapeutics, Inc. (AVTX)
19.01
-0.33
(-1.71%)
USD |
NASDAQ |
Sep 03, 16:00
19.01
0.00 (0.00%)
After-Hours: 20:00
Avalo Therapeutics Research and Development Expense (TTM) : 64.35M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 64.35M |
| March 31, 2026 | 55.01M |
| December 31, 2025 | 50.08M |
| September 30, 2025 | 45.00M |
| June 30, 2025 | 40.92M |
| March 31, 2025 | 31.44M |
| December 31, 2024 | 24.44M |
| September 30, 2024 | 18.12M |
| June 30, 2024 | 9.833M |
| March 31, 2024 | 9.89M |
| December 31, 2023 | 13.78M |
| September 30, 2023 | 18.09M |
| June 30, 2023 | 23.88M |
| March 31, 2023 | 27.73M |
| December 31, 2022 | 31.31M |
| September 30, 2022 | 36.65M |
| June 30, 2022 | 40.16M |
| March 31, 2022 | 44.21M |
| December 31, 2021 | 59.84M |
| September 30, 2021 | 60.96M |
| June 30, 2021 | 59.28M |
| March 31, 2021 | 52.63M |
| Date | Value |
|---|---|
| December 31, 2020 | 32.19M |
| September 30, 2020 | 21.30M |
| June 30, 2020 | 16.14M |
| March 31, 2020 | 13.62M |
| September 30, 2019 | 10.86M |
| June 30, 2019 | 10.17M |
| March 31, 2019 | 7.538M |
| December 31, 2018 | 5.786M |
| September 30, 2018 | 5.741M |
| June 30, 2018 | 5.658M |
| March 31, 2018 | 5.069M |
| December 31, 2017 | 4.372M |
| September 30, 2017 | 3.184M |
| June 30, 2017 | 6.801M |
| March 31, 2017 | 8.809M |
| December 31, 2016 | 10.15M |
| September 30, 2016 | 11.13M |
| June 30, 2016 | 7.783M |
| March 31, 2016 | 7.157M |
| December 31, 2015 | 6.587M |
| September 30, 2015 | 7.697M |
| June 30, 2015 | 9.209M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Incyte Corp. | 2.098B |
| AbbVie, Inc. | 9.714B |
| Rezolute, Inc. | 59.77M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |